These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 35977268)

  • 1. Estimation of the Share of Net Expenditures on Insulin Captured by US Manufacturers, Wholesalers, Pharmacy Benefit Managers, Pharmacies, and Health Plans From 2014 to 2018.
    Van Nuys K; Ribero R; Ryan M; Sood N
    JAMA Health Forum; 2021 Nov; 2(11):e213409. PubMed ID: 35977268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimated Changes in Manufacturer and Health Care Organization Revenue Following List Price Reductions for Hepatitis C Treatments.
    Dickson S; Reynolds I
    JAMA Netw Open; 2019 Jul; 2(7):e196541. PubMed ID: 31276176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of mail-order with community pharmacy in plan sponsor cost and member cost in two large pharmacy benefit plans.
    Johnsrud M; Lawson KA; Shepherd MD
    J Manag Care Pharm; 2007 Mar; 13(2):122-34. PubMed ID: 17330973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in List Prices, Net Prices, and Discounts for Branded Drugs in the US, 2007-2018.
    Hernandez I; San-Juan-Rodriguez A; Good CB; Gellad WF
    JAMA; 2020 Mar; 323(9):854-862. PubMed ID: 32125403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The relationship between pharmacy benefit managers (PBMs) and the cost of therapies in the US pharmaceutical market: A policy primer for clinicians.
    Schulman KA; Dabora M
    Am Heart J; 2018 Dec; 206():113-122. PubMed ID: 30447542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Branded Prescription Drug Rebate Size and Patient Out-of-Pocket Costs in a Nationally Representative Sample, 2007-2018.
    Yeung K; Dusetzina SB; Basu A
    JAMA Netw Open; 2021 Jun; 4(6):e2113393. PubMed ID: 34125219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation Between Changes in Brand-Name Drug Prices and Patient Out-of-Pocket Costs.
    Rome BN; Feldman WB; Desai RJ; Kesselheim AS
    JAMA Netw Open; 2021 May; 4(5):e218816. PubMed ID: 33944925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient and Payer Incentives to Use Patented Brand-Name Drugs vs Authorized Generic Drugs in Medicare Part D.
    Dusetzina SB; Sarpatwari A; Carrier MA; Hansen RA; Keating NL; Huskamp HA
    JAMA Intern Med; 2021 Dec; 181(12):1605-1611. PubMed ID: 34661600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacy Benefit Managers: History, Business Practices, Economics, and Policy.
    Mattingly TJ; Hyman DA; Bai G
    JAMA Health Forum; 2023 Nov; 4(11):e233804. PubMed ID: 37921745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug rebates in Medicare Part D: Excess patient costs in the case of hepatitis C treatments.
    Arambadjis Y; Butler M; Huckfeldt P; Schondelmeyer S
    Res Social Adm Pharm; 2020 Sep; 16(9):1290-1293. PubMed ID: 31147206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of Specialty Drugs in Rising Drug Prices for Medicare Part D.
    Hayford TB
    JAMA Health Forum; 2024 May; 5(5):e241188. PubMed ID: 38787543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Do generics offer significant savings to the UK National Health Service?
    Kanavos P
    Curr Med Res Opin; 2007 Jan; 23(1):105-16. PubMed ID: 17257472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in Drug List Prices and Amounts Paid by Patients and Insurers.
    Yang EJ; Galan E; Thombley R; Lin A; Seo J; Tseng CW; Resneck JS; Bach PB; Dudley RA
    JAMA Netw Open; 2020 Dec; 3(12):e2028510. PubMed ID: 33295971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of Commercial and Mandatory Discounts in the Gross-to-Net Bubble for the Top Insulin Products From 2012 to 2019.
    Dickson SR; Gabriel N; Gellad WF; Hernandez I
    JAMA Netw Open; 2023 Jun; 6(6):e2318145. PubMed ID: 37314806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimates of Medicaid and Non-Medicaid Net Prices of Top-Selling Brand-name Drugs Incorporating Best Price Rebates, 2015 to 2019.
    Clemans-Cope L; Epstein M; Banthin J; Kesselheim AS; Hwang TJ
    JAMA Health Forum; 2023 Jan; 4(1):e225012. PubMed ID: 36637815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Addressing High Drug Prices by Reforming Pharmacy Benefit Managers.
    Rome BN
    J Law Med Ethics; 2023; 51(S2):46-51. PubMed ID: 38433673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Community pharmacy and mail order cost and utilization for 90-day maintenance medication prescriptions.
    Khandelwal N; Duncan I; Rubinstein E; Ahmed T; Pegus C
    J Manag Care Pharm; 2012 Apr; 18(3):247-55. PubMed ID: 22468733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacy Benefit Manager Pricing and Spread Pricing for High-Utilization Generic Drugs.
    Mattingly TJ; Ben-Umeh KC; Bai G; Anderson GF
    JAMA Health Forum; 2023 Oct; 4(10):e233660. PubMed ID: 37862035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A primer on brand-name prescription drug reimbursement in the United States.
    Hernandez I; Hung A
    J Manag Care Spec Pharm; 2024 Jan; 30(1):99-106. PubMed ID: 38153864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Contribution of Price Growth to Pharmaceutical Revenue Growth in the United States: Evidence from Medicines Sold in Retail Pharmacies.
    Kakani P; Chernew M; Chandra A
    J Health Polit Policy Law; 2022 Dec; 47(6):629-648. PubMed ID: 35867538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.